Ex vivo evaluation of the serotonin 1A receptor partial agonist [³H]CUMI-101 in awake rats.
Palner, Mikael; Underwood, Mark D; Kumar, Dileep J S; Arango, Victoria; Knudsen, Gitte M; John Mann, J; Parsey, Ramin V.
; 65(8): 715-23, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21108237
Marmoset Serotonin 5-HT1A Receptor Mapping with a Biased Agonist PET Probe 18F-F13714: Comparison with an Antagonist Tracer 18F-MPPF in Awake and Anesthetized States.
Synthesis and evaluation of two new candidate high-affinity full agonist PET radioligands for imaging 5-HT<sub>1B</sub> receptors.
Cerebral serotonin release correlates with [<sup>11</sup>C]AZ10419369 PET measures of 5-HT<sub>1B</sub> receptor binding in the pig brain.
Theory-based analysis of clinical efficacy of triptans using receptor occupancy.
Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT<sub>1A</sub> weak partial agonistic activity showing the antidepressant-like effect.
Biodistribution, toxicology, and radiation dosimetry of 5-HT1A-receptor agonist positron emission tomography ligand [11C]CUMI-101.
Intranasal zolmitriptan for the treatment of acute migraine.
The pharmacodynamic effects of combined administration of flibanserin and alcohol.
Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks.
Clinical implications for breath-powered powder sumatriptan intranasal treatment.